|
Galanthamine
HBr API
|
|
|
|
Haorui supplies Galanthamine HBr
API (Active Pharmaceutical Ingredients) to
pharmaceutical industry. Our bulk Galanthamine
HBr actives is produced by GMP facility.
Welcome
to contact
us
for product detail.
|
|
|
|
The following information is
provided for general information purposes ONLY.
|
|
|
|
What is Galanthamine?
|
|
Galanthamine
comes from the bulbs of a spring flower called
common snowdrop. The herb is available as a chemical
synthetic in coated tablets and ampules. Some
research shows assistance with Alzheimer's disease
with this herb; however, more research is underway
at this time.
|
|
|
|
A
cholinesterase inhibitor derived from the plant, Galanthus. It has been used to reverse the muscular
effects of Gallamine Triethiodide and Tubocurarine
and has been studied as a treatment for Alzheimer
diseas and other central
nervous system disorders.
|
|
|
|
How does Galanthamine work?
|
|
Many people use
Galanthamine for the following:
·
Alzheimer's disease
·
Myasthenia gravis
·
Post-polio Paralysis
·
To reverse neuromuscular blockade (in which drugs
are given to stop unwanted muscle movement)
|
|
|
|
The history of Galanthamine
|
|
Derived
from bulbs of the common snowdrop and several
Amaryllidaceae plants, (-)-galanthamine (GAL) has
long been used in anaesthetics to reverse
neuromuscular paralysis induced by turbocurarine-like
muscle relaxants and more recently, has been shown
to attenuate drug- and lesion-induced cognitive
deficits in animal models of learning and memory.
|
|
|
|
What is Galanthamine used
for?
|
|
GAL directly inhibits
acetylcholinesterase activity, while demonstrating
much weaker activity on butyrylcholinesterase (BuChE).
GAL also stimulates pre- and postsynaptic nicotinic
receptors, although the clinical significance of
this finding is yet unclear. Numerous variants and
analogues of GAL have also been developed, with
varying potency in inhibiting AChE activity. GAL is
readily absorbed after oral administration, with a
t(max) of 52 min and a plasma elimination t(1/2) of
5.7 h. The efficacy of GAL administered to
Alzheimer's disease (AD) patients has been well
demonstrated by large-scale clinical trials.
Typical of AChEIs, the most common adverse events
associated with GAL are nausea and vomiting.
In conclusion, evidence to date suggests
galanthamine to be similar to other AChEIs in
improving cognitive function in AD patients.
|
|
|
|
Disclaimer:
|
|
Information on
this page is provided for general information
purposes. You should not make a clinical treatment
decision based on information contained in this page
without consulting other references including the
package insert of the drug, textbooks and where
relevant, expert opinion. We cannot be held
responsible for any errors you make in administering
drugs mentioned on this page, nor for use of any
erroneous information contained on this page.
|
